Ovid Therapeutics (NASDAQ:OVID) announced its earnings results on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.07, MarketWatch Earnings reports.
Shares of OVID stock traded down $0.41 during trading hours on Friday, reaching $5.15. 24,520 shares of the company were exchanged, compared to its average volume of 77,724. Ovid Therapeutics has a fifty-two week low of $4.74 and a fifty-two week high of $12.44. The firm has a market capitalization of $134.00 million, a price-to-earnings ratio of -1.54 and a beta of 1.15.
A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 15th. ValuEngine upgraded shares of Ovid Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price on the stock in a research report on Saturday, August 18th. Finally, Piper Jaffray Companies set a $20.00 target price on shares of Ovid Therapeutics and gave the stock a “buy” rating in a research report on Sunday, August 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Ovid Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.75.
COPYRIGHT VIOLATION WARNING: “Ovid Therapeutics (OVID) Releases Earnings Results, Beats Estimates By $0.07 EPS” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://sportsperspectives.com/2018/11/09/ovid-therapeutics-ovid-releases-earnings-results-beats-estimates-by-0-07-eps.html.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Recommended Story: What is the Dividend Aristocrat Index?
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.